Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Docetaxel.

Farha NG, Kasi A.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 Feb 6.

2.

Chemotherapy for advanced gastric cancer.

Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S.

Cochrane Database Syst Rev. 2017 Aug 29;8:CD004064. doi: 10.1002/14651858.CD004064.pub4. Review.

PMID:
28850174
3.

Capecitabine: a review.

Walko CM, Lindley C.

Clin Ther. 2005 Jan;27(1):23-44. Review.

PMID:
15763604
4.
5.

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

Van Cutsem E, Boni C, Tabernero J, Massuti B, Middleton G, Dane F, Reichardt P, Pimentel FL, Cohn A, Follana P, Clemens M, Zaniboni A, Moiseyenko V, Harrison M, Richards DA, Prenen H, Pernot S, Ecstein-Fraisse E, Hitier S, Rougier P.

Ann Oncol. 2015 Jan;26(1):149-56.

PMID:
25416687
6.

Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.

Sym SJ, Ryu MH, Kang HJ, Lee SS, Chang HM, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK.

Cancer Chemother Pharmacol. 2010 Jul;66(2):373-80. doi: 10.1007/s00280-009-1171-x. Epub 2009 Nov 21.

PMID:
19936751
7.

Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.

Bilici A, Selcukbiricik F, Demir N, Oven Ustaalioglu BB, Dikilitas M, Yildiz O.

Asian Pac J Cancer Prev. 2014;15(20):8661-6.

8.

Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.

Andersen M, Schønnemann KR, Yilmaz M, Jensen HA, Vestermark LW, Pfeiffer P.

Acta Oncol. 2010 Nov;49(8):1246-52. doi: 10.3109/02841861003767521. Epub 2010 Apr 29.

PMID:
20429725
9.

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.

Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K.

Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9.

PMID:
29033099
10.
11.

Docetaxel in the treatment of gastric cancer.

Thuss-Patience PC, Kretzschmar A, Reichardt P.

Future Oncol. 2006 Oct;2(5):603-20. Review.

PMID:
17026452
12.

Docetaxel/Oxaliplatin/Capecitabine (TEX) triplet followed by continuation monotherapy in advanced gastric cancer.

Ostwal V, Bose S, Sirohi B, Poladia B, Sahu A, Bhargava P, Doshi V, Dusane R, Nashikkar C, Shrikhande SV, Ramaswamy A.

Indian J Cancer. 2018 Jan-Mar;55(1):88-93. doi: 10.4103/ijc.IJC_353_17.

13.

A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer.

Atmaca A, Al-Batran SE, Werner D, Pauligk C, Güner T, Koepke A, Bernhard H, Wenzel T, Banat AG, Brueck P, Caca K, Prasnikar N, Kullmann F, Günther Derigs H, Koenigsmann M, Dingeldein G, Neuhaus T, Jäger E.

Br J Cancer. 2013 Feb 5;108(2):265-70. doi: 10.1038/bjc.2012.555. Epub 2013 Jan 17.

14.

Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.

Binder D, Schweisfurth H, Grah C, Schäper C, Temmesfeld-Wollbrück B, Siebert G, Suttorp N, Beinert T.

Cancer Chemother Pharmacol. 2007 Jun;60(1):143-50. Epub 2006 Oct 10.

PMID:
17031643
15.
16.

Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.

Di Lauro L, Vici P, Belli F, Tomao S, Fattoruso SI, Arena MG, Pizzuti L, Giannarelli D, Paoletti G, Barba M, Sergi D, Maugeri-Saccà M.

Gastric Cancer. 2014 Oct;17(4):718-24. doi: 10.1007/s10120-013-0321-3. Epub 2013 Dec 8.

PMID:
24318671
17.

Seven-day capecitabine plus docetaxel and oxaliplatin regimen for the treatment of advanced gastric cancer: A phase-I clinical trial.

Liang R, Lin Y, Li Y, Li Q, Yuan C, Liao X, Liao S, Zhang J, Liu Z.

Mol Clin Oncol. 2017 Apr;6(4):622-626. doi: 10.3892/mco.2017.1161. Epub 2017 Feb 9.

18.

Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.

Chu Q, Vincent M, Logan D, Mackay JA, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.

Lung Cancer. 2005 Dec;50(3):355-74. Epub 2005 Aug 31. Review.

PMID:
16139391
19.

Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer.

Fan Y, Xu BH, Yuan P, Ma F, Wang JY, Ding XY, Zhang P, Li Q, Cai RG.

Ann Oncol. 2013 May;24(5):1219-25. doi: 10.1093/annonc/mds603. Epub 2012 Dec 5.

PMID:
23223332
20.

A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.

Silva O, Lopes G, Morgenzstern D, Lobo C, Doliny P, Santos E, Abdullah S, Gautam U, Reis I, Welsh C, Slingerland J, Hurley J, Gluck S.

Clin Breast Cancer. 2008 Apr;8(2):162-7. doi: 10.3816/CBC.2008.n.017.

PMID:
18621613

Supplemental Content

Support Center